HK1217105A1 - 些氨基烷基氨基葡糖苷磷酸酯化合物及其用途 - Google Patents
些氨基烷基氨基葡糖苷磷酸酯化合物及其用途Info
- Publication number
- HK1217105A1 HK1217105A1 HK16105082.0A HK16105082A HK1217105A1 HK 1217105 A1 HK1217105 A1 HK 1217105A1 HK 16105082 A HK16105082 A HK 16105082A HK 1217105 A1 HK1217105 A1 HK 1217105A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- phosphate compounds
- aminoalkyl glucosaminide
- glucosaminide phosphate
- certain aminoalkyl
- certain
- Prior art date
Links
- -1 aminoalkyl glucosaminide phosphate compounds Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
- C07H5/02—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H11/00—Compounds containing saccharide radicals esterified by inorganic acids; Metal salts thereof
- C07H11/04—Phosphates; Phosphites; Polyphosphates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
- C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
- C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Lift-Guide Devices, And Elevator Ropes And Cables (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/888,683 US7960522B2 (en) | 2003-01-06 | 2004-07-08 | Certain aminoalkyl glucosaminide phosphate compounds and their use |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1217105A1 true HK1217105A1 (zh) | 2016-12-23 |
Family
ID=35839700
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK07104639.2A HK1099308A1 (zh) | 2004-07-08 | 2007-04-30 | 些氨烷基氨基葡糖苷磷酸酯化合物及其應用 |
HK16105082.0A HK1217105A1 (zh) | 2004-07-08 | 2016-05-04 | 些氨基烷基氨基葡糖苷磷酸酯化合物及其用途 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK07104639.2A HK1099308A1 (zh) | 2004-07-08 | 2007-04-30 | 些氨烷基氨基葡糖苷磷酸酯化合物及其應用 |
Country Status (24)
Country | Link |
---|---|
US (2) | US7960522B2 (zh) |
EP (2) | EP2940027A1 (zh) |
JP (1) | JP2008505897A (zh) |
CN (1) | CN101010328A (zh) |
AU (1) | AU2005272076B2 (zh) |
BR (1) | BRPI0513144A (zh) |
CA (1) | CA2573059A1 (zh) |
CY (1) | CY1116571T1 (zh) |
DK (1) | DK1776375T3 (zh) |
ES (1) | ES2541306T3 (zh) |
HK (2) | HK1099308A1 (zh) |
HU (1) | HUE025324T2 (zh) |
IL (1) | IL180599A (zh) |
MA (1) | MA28758B1 (zh) |
MX (1) | MX2007000331A (zh) |
NO (1) | NO340869B1 (zh) |
NZ (1) | NZ552790A (zh) |
PL (1) | PL1776375T3 (zh) |
PT (1) | PT1776375E (zh) |
RU (1) | RU2007104781A (zh) |
SI (1) | SI1776375T1 (zh) |
TR (1) | TR200701350T1 (zh) |
WO (1) | WO2006016997A2 (zh) |
ZA (2) | ZA200700996B (zh) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030139356A1 (en) * | 2001-05-18 | 2003-07-24 | Persing David H. | Prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compounds |
US20090215710A1 (en) * | 2007-09-24 | 2009-08-27 | Reliance Life Sciences Pvt. Ltd. | Carbohydrate based toll-like receptor (tlr) antagonists |
JP5562939B2 (ja) | 2008-04-09 | 2014-07-30 | ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル | アクチン細胞骨格再編成及び細胞間ギャップ形成調節の方法 |
EP2373342B1 (en) | 2008-12-23 | 2015-09-16 | GlaxoSmithKline Biologicals S.A. | Lipid a mimetics for use in inducing an immune response |
CA2757998A1 (en) * | 2009-04-09 | 2010-10-14 | The University Of North Carolina At Chapel Hill | Methods of treating edema related to ischemia-reperfusion |
GB201009273D0 (en) | 2010-06-03 | 2010-07-21 | Glaxosmithkline Biolog Sa | Novel vaccine |
GB201101331D0 (en) | 2011-01-26 | 2011-03-09 | Glaxosmithkline Biolog Sa | Compositions and uses |
GB201113570D0 (en) * | 2011-08-05 | 2011-09-21 | Glaxosmithkline Biolog Sa | Vaccine |
CA2905162A1 (en) | 2013-03-15 | 2014-09-18 | Glaxosmithkline Biologicals S.A. | Composition containing buffered aminoalkyl glucosaminide phosphate derivatives and its use for enhancing an immune response |
EP3110401A4 (en) | 2014-02-25 | 2017-10-25 | Merck Sharp & Dohme Corp. | Lipid nanoparticle vaccine adjuvants and antigen delivery systems |
JP2017511802A (ja) | 2014-03-12 | 2017-04-27 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 免疫原リポソーム製剤 |
AU2015228463A1 (en) | 2014-03-12 | 2016-10-27 | Glaxosmithkline Biologicals S.A. | Liposomal compositions for mucosal delivery |
MA41414A (fr) | 2015-01-28 | 2017-12-05 | Centre Nat Rech Scient | Protéines de liaison agonistes d' icos |
CA2988654A1 (en) | 2015-06-12 | 2016-12-15 | Glaxosmithkline Biologicals S.A. | Adenovirus polynucleotides and polypeptides |
WO2017013603A1 (en) | 2015-07-21 | 2017-01-26 | Glaxosmithkline Biologicals Sa | Adjuntive immunotherapy for the prevention or treatment of infectious disease |
JP2018522053A (ja) * | 2015-08-06 | 2018-08-09 | グラクソスミスクライン、インテレクチュアル、プロパテ | Tlr4アゴニストおよびその組成物ならびに癌の処置におけるそれらの使用 |
WO2017021912A1 (en) | 2015-08-06 | 2017-02-09 | Glaxosmithkline Intellectual Property Development Limited | Combined tlrs modulators with anti ox40 antibodies |
TW201716084A (zh) | 2015-08-06 | 2017-05-16 | 葛蘭素史克智慧財產發展有限公司 | 組合物及其用途與治療 |
MX363780B (es) | 2015-12-03 | 2019-04-03 | Glaxosmithkline Ip Dev Ltd | Dinucleótidos de purina cíclica como moduladores del estimulador de los genes de interferón. |
WO2017098421A1 (en) | 2015-12-08 | 2017-06-15 | Glaxosmithkline Intellectual Property Development Limited | Benzothiadiazine compounds |
WO2017153952A1 (en) | 2016-03-10 | 2017-09-14 | Glaxosmithkline Intellectual Property Development Limited | 5-sulfamoyl-2-hydroxybenzamide derivatives |
NZ745957A (en) | 2016-04-07 | 2020-07-31 | Glaxosmithkline Ip Dev Ltd | Heterocyclic amides useful as protein modulators |
AU2017247806B2 (en) | 2016-04-07 | 2019-11-14 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides useful as protein modulators |
CN109328188A (zh) | 2016-05-05 | 2019-02-12 | 葛兰素史密斯克莱知识产权(第2 号)有限公司 | Zeste增强子同源物2抑制剂 |
KR20190028540A (ko) | 2016-07-20 | 2019-03-18 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | Perk 억제제로서의 이소퀴놀린 유도체 |
CA3045752A1 (en) | 2016-12-01 | 2018-06-07 | Glaxosmithkline Intellectual Property Development Limited | Methods of treating cancer |
WO2019021208A1 (en) | 2017-07-27 | 2019-01-31 | Glaxosmithkline Intellectual Property Development Limited | USEFUL INDAZOLE DERIVATIVES AS PERK INHIBITORS |
WO2019053617A1 (en) | 2017-09-12 | 2019-03-21 | Glaxosmithkline Intellectual Property Development Limited | CHEMICAL COMPOUNDS |
CA3077337A1 (en) | 2017-10-05 | 2019-04-11 | Glaxosmithkline Intellectual Property Development Limited | Modulators of stimulator of interferon genes (sting) |
WO2019069269A1 (en) | 2017-10-05 | 2019-04-11 | Glaxosmithkline Intellectual Property Development Limited | INTERFERON GENE STIMULATOR MODULATORS USEFUL IN THE TREATMENT OF HIV |
BR112020016314A2 (pt) | 2018-02-12 | 2020-12-15 | Inimmune Corporation | Compostos ou um sais farmaceuticamente aceitáveis, composição farmacêutica, kit, e, métodos para elicitar, intensificar ou modificar uma resposta imunológica, para tratar, prevenir ou reduzir a suscetibilidade a câncer, para tratar, prevenir ou reduzir a suscetibilidade a uma doença infecciosa, para tratar, prevenir ou reduzir a suscetibilidade a uma alergia, para tratar, prevenir ou reduzir a suscetibilidade a uma afecção autoimune, para tratar, prevenir ou reduzir a suscetibilidade em um sujeito à infecção bacteriana, viral, priônica, autoimunidade, câncer ou alergia, para tratar, prevenir ou reduzir a suscetibilidade à autoimunidade, alergia, reperfusão de isquemia ou sepse, para tratar, prevenir ou reduzir a gravidade de ataques epiléticos e para tratar, prevenir ou reduzir a suscetibilidade a doenças oculares como degeneração macular, hipertensão ocular e infecção ocular |
GB201807924D0 (en) | 2018-05-16 | 2018-06-27 | Ctxt Pty Ltd | Compounds |
WO2020007760A1 (en) * | 2018-07-03 | 2020-01-09 | Glaxosmithkline Intellectual Property Development Limited | Tlr4 compounds or pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions or formulations, methods of preparation, treatment or uses |
WO2020030571A1 (en) | 2018-08-06 | 2020-02-13 | Glaxosmithkline Intellectual Property Development Limited | Combinations of a pd-1 antibody and a tlr4 modulator and uses thereof |
WO2020031087A1 (en) | 2018-08-06 | 2020-02-13 | Glaxosmithkline Intellectual Property Development Limited | Combination therapy |
WO2020030570A1 (en) | 2018-08-06 | 2020-02-13 | Glaxosmithkline Intellectual Property Development Limited | Combinations of an ox40 antibody and a tlr4 modulator and uses thereof |
EP3886901A1 (en) | 2018-11-29 | 2021-10-06 | GlaxoSmithKline Biologicals S.A. | Methods for manufacturing an adjuvant |
BR112021023292A2 (pt) | 2019-05-23 | 2022-02-08 | The Univ Of Montana | Composto, formulação, composição de vacina, composição farmacêutica, e, método para modular uma resposta imune em um indivíduo |
KR20220026585A (ko) | 2019-06-26 | 2022-03-04 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | Il1rap 결합 단백질 |
GB201910305D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
GB201910304D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
KR20220035457A (ko) | 2019-07-21 | 2022-03-22 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 치료 바이러스 백신 |
WO2021018941A1 (en) | 2019-07-31 | 2021-02-04 | Glaxosmithkline Intellectual Property Development Limited | Methods of treating cancer |
WO2021043961A1 (en) | 2019-09-06 | 2021-03-11 | Glaxosmithkline Intellectual Property Development Limited | Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and chemotherapy |
CA3092525A1 (en) | 2019-09-09 | 2021-03-09 | Glaxosmithkline Biologicals S.A. | Immunotherapeutic compositions |
AU2020355614A1 (en) | 2019-09-27 | 2022-04-14 | Glaxosmithkline Intellectual Property Development Limited | Antigen binding proteins |
EP4161570A1 (en) | 2020-06-05 | 2023-04-12 | GlaxoSmithKline Biologicals S.A. | Modified betacoronavirus spike proteins |
US20240325517A1 (en) | 2020-09-15 | 2024-10-03 | The University Of Montana | Compositions and methods targeting filamentous bacteriophage |
AU2021380287A1 (en) * | 2020-11-11 | 2023-06-22 | Daiichi Sankyo Company, Limited | Novel aminoalkyl glucosaminide 4-phosphate derivative |
EP4032547A1 (en) | 2021-01-20 | 2022-07-27 | GlaxoSmithKline Biologicals S.A. | Hsv1 fce derived fragements for the treatment of hsv |
MX2023010067A (es) | 2021-03-02 | 2023-09-06 | Glaxosmithkline Ip Dev Ltd | Piridinas sustituidas como inhibidores de dnmt1. |
WO2022208353A1 (en) | 2021-03-31 | 2022-10-06 | Glaxosmithkline Intellectual Property Development Limited | Antigen binding proteins and combinations thereof |
Family Cites Families (100)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4769330A (en) | 1981-12-24 | 1988-09-06 | Health Research, Incorporated | Modified vaccinia virus and methods for making and using the same |
US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
US4866034A (en) | 1982-05-26 | 1989-09-12 | Ribi Immunochem Research Inc. | Refined detoxified endotoxin |
US4436727A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
US4987237A (en) | 1983-08-26 | 1991-01-22 | Ribi Immunochem Research, Inc. | Derivatives of monophosphoryl lipid A |
US5128326A (en) | 1984-12-06 | 1992-07-07 | Biomatrix, Inc. | Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same |
US4883750A (en) | 1984-12-13 | 1989-11-28 | Applied Biosystems, Inc. | Detection of specific sequences in nucleic acids |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
GB8508845D0 (en) | 1985-04-04 | 1985-05-09 | Hoffmann La Roche | Vaccinia dna |
US4777127A (en) | 1985-09-30 | 1988-10-11 | Labsystems Oy | Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus |
US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
US4877611A (en) | 1986-04-15 | 1989-10-31 | Ribi Immunochem Research Inc. | Vaccine containing tumor antigens and adjuvants |
GB8702816D0 (en) | 1987-02-07 | 1987-03-11 | Al Sumidaie A M K | Obtaining retrovirus-containing fraction |
US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
AU622104B2 (en) | 1987-03-11 | 1992-04-02 | Sangtec Molecular Diagnostics Ab | Method of assaying of nucleic acids, a reagent combination and kit therefore |
IL86724A (en) | 1987-06-19 | 1995-01-24 | Siska Diagnostics Inc | Methods and kits for amplification and testing of nucleic acid sequences |
US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
DE10399031I1 (de) | 1987-08-28 | 2004-01-29 | Health Research Inc | Rekombinante Viren. |
WO1989001973A2 (en) | 1987-09-02 | 1989-03-09 | Applied Biotechnology, Inc. | Recombinant pox virus for immunization against tumor-associated antigens |
CA1323293C (en) | 1987-12-11 | 1993-10-19 | Keith C. Backman | Assay using template-dependent nucleic acid probe reorganization |
JP2846018B2 (ja) | 1988-01-21 | 1999-01-13 | ジェネンテク,インコーポレイテッド | 核酸配列の増幅および検出 |
CA1340807C (en) | 1988-02-24 | 1999-11-02 | Lawrence T. Malek | Nucleic acid amplification process |
AP129A (en) | 1988-06-03 | 1991-04-17 | Smithkline Biologicals S A | Expression of retrovirus gag protein eukaryotic cells |
US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
US5549910A (en) | 1989-03-31 | 1996-08-27 | The Regents Of The University Of California | Preparation of liposome and lipid complex compositions |
US5725871A (en) | 1989-08-18 | 1998-03-10 | Danbiosyst Uk Limited | Drug delivery compositions comprising lysophosphoglycerolipid |
EP1001032A3 (en) | 1989-08-18 | 2005-02-23 | Chiron Corporation | Recombinant retroviruses delivering vector constructs to target cells |
KR920007887B1 (ko) | 1989-08-29 | 1992-09-18 | 스즈키 지도오샤 고오교오 가부시키가이샤 | 내연기관의 배기가스 정화장치 |
US5707644A (en) | 1989-11-04 | 1998-01-13 | Danbiosyst Uk Limited | Small particle compositions for intranasal drug delivery |
EP0550436A1 (en) | 1989-11-06 | 1993-07-14 | Alkermes Controlled Therapeutics, Inc. | Protein microspheres and methods of using them |
US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
EP0500799B1 (en) | 1989-11-16 | 1998-01-14 | Duke University | Particle mediated transformation of animal skin tissue cells |
FR2658432B1 (fr) | 1990-02-22 | 1994-07-01 | Medgenix Group Sa | Microspheres pour la liberation controlee des substances hydrosolubles et procede de preparation. |
US5466468A (en) | 1990-04-03 | 1995-11-14 | Ciba-Geigy Corporation | Parenterally administrable liposome formulation comprising synthetic lipids |
SE466259B (sv) | 1990-05-31 | 1992-01-20 | Arne Forsgren | Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal |
WO1992001070A1 (en) | 1990-07-09 | 1992-01-23 | The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce | High efficiency packaging of mutant adeno-associated virus using amber suppressions |
JP3218637B2 (ja) | 1990-07-26 | 2001-10-15 | 大正製薬株式会社 | 安定なリポソーム水懸濁液 |
MY109299A (en) | 1990-08-15 | 1996-12-31 | Virogenetics Corp | Recombinant pox virus encoding flaviviral structural proteins |
JP2958076B2 (ja) | 1990-08-27 | 1999-10-06 | 株式会社ビタミン研究所 | 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法 |
US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
ATE237694T1 (de) | 1991-08-20 | 2003-05-15 | Us Gov Health & Human Serv | Adenovirus vermittelter gentransfer in den gastrointestinaltrakt |
US5593969A (en) * | 1991-09-03 | 1997-01-14 | Igen Incorporated | Lipid-A analogs: monosaccharide and dissaccharide compounds for inhibiting binding of lipid A receptors to lipid A receptors |
US5530113A (en) | 1991-10-11 | 1996-06-25 | Eisai Co., Ltd. | Anti-endotoxin compounds |
US5756353A (en) | 1991-12-17 | 1998-05-26 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol-and liposome-based delivery |
US5912015A (en) | 1992-03-12 | 1999-06-15 | Alkermes Controlled Therapeutics, Inc. | Modulated release from biocompatible polymers |
DK0641192T3 (da) | 1992-05-18 | 1998-03-02 | Minnesota Mining & Mfg | Anordning til transmucosal lægemiddelafgivelse |
US5792451A (en) | 1994-03-02 | 1998-08-11 | Emisphere Technologies, Inc. | Oral drug delivery compositions and methods |
US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
US5633234A (en) | 1993-01-22 | 1997-05-27 | The Johns Hopkins University | Lysosomal targeting of immunogens |
US5654186A (en) | 1993-02-26 | 1997-08-05 | The Picower Institute For Medical Research | Blood-borne mesenchymal cells |
FR2702160B1 (fr) | 1993-03-02 | 1995-06-02 | Biovecteurs As | Vecteurs particulaires synthétiques et procédé de préparation. |
FR2704145B1 (fr) | 1993-04-21 | 1995-07-21 | Pasteur Institut | Vecteur particulaire et composition pharmaceutique le contenant. |
US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
US6015686A (en) | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
EP0690732B1 (en) | 1994-01-21 | 2003-01-29 | Powderject Vaccines, Inc. | Gas driven gene delivery instrument |
US5505947A (en) | 1994-05-27 | 1996-04-09 | The University Of North Carolina At Chapel Hill | Attenuating mutations in Venezuelan Equine Encephalitis virus |
DK0772619T4 (da) | 1994-07-15 | 2011-02-21 | Univ Iowa Res Found | Immunmodulatoriske oligonukleotider |
FR2723849B1 (fr) | 1994-08-31 | 1997-04-11 | Biovector Therapeutics Sa | Procede pour augmenter l'immunogenicite, produit obtenu et composition pharmaceutique |
US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
GB9502879D0 (en) | 1995-02-14 | 1995-04-05 | Oxford Biosciences Ltd | Particle delivery |
US5580579A (en) | 1995-02-15 | 1996-12-03 | Nano Systems L.L.C. | Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers |
IE80468B1 (en) | 1995-04-04 | 1998-07-29 | Elan Corp Plc | Controlled release biodegradable nanoparticles containing insulin |
CA2220530A1 (en) | 1995-06-02 | 1996-12-05 | Incyte Pharmaceuticals, Inc. | Improved method for obtaining full-length cdna sequences |
US5738868A (en) | 1995-07-18 | 1998-04-14 | Lipogenics Ltd. | Liposome compositions and kits therefor |
CA2230494A1 (en) | 1995-08-31 | 1997-03-06 | Alkermes Controlled Therapeutics Inc. | Composition for sustained release of an agent |
US6506792B1 (en) * | 1997-03-04 | 2003-01-14 | Sterix Limited | Compounds that inhibit oestrone sulphatase and/or aromatase and methods for making and using |
US5856462A (en) | 1996-09-10 | 1999-01-05 | Hybridon Incorporated | Oligonucleotides having modified CpG dinucleosides |
US5811407A (en) | 1997-02-19 | 1998-09-22 | The University Of North Carolina At Chapel Hill | System for the in vivo delivery and expression of heterologous genes in the bone marrow |
US6113918A (en) * | 1997-05-08 | 2000-09-05 | Ribi Immunochem Research, Inc. | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
US6303347B1 (en) | 1997-05-08 | 2001-10-16 | Corixa Corporation | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors |
US7541020B2 (en) * | 1997-05-08 | 2009-06-02 | Corixa Corporation | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors |
US6764840B2 (en) | 1997-05-08 | 2004-07-20 | Corixa Corporation | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors |
US6355257B1 (en) * | 1997-05-08 | 2002-03-12 | Corixa Corporation | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
US7063967B2 (en) * | 1997-05-08 | 2006-06-20 | Corixa Corporation | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors |
US5993412A (en) | 1997-05-19 | 1999-11-30 | Bioject, Inc. | Injection apparatus |
KR100241901B1 (ko) | 1997-08-28 | 2000-02-01 | 윤종용 | 핸드셋과 핸즈프리킷 공용 음성인식기의 등록 엔트리 관리방법 |
US5989463A (en) | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
SE512663C2 (sv) | 1997-10-23 | 2000-04-17 | Biogram Ab | Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer |
GB9727262D0 (en) | 1997-12-24 | 1998-02-25 | Smithkline Beecham Biolog | Vaccine |
JP2002511423A (ja) | 1998-04-09 | 2002-04-16 | スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム | ワクチン |
US6355251B1 (en) | 1999-06-15 | 2002-03-12 | Mark Zamoyski | Compositions and methods for epidermal chemexfoliation |
US7491707B1 (en) * | 1999-11-15 | 2009-02-17 | Biomira, Inc. | Synthetic lipid-a-analogs and uses thereof |
US6699846B2 (en) | 2000-03-17 | 2004-03-02 | Corixa Corporation | Mono- and disaccharides for the treatment of nitric oxide related disorders |
JP5004261B2 (ja) | 2000-05-19 | 2012-08-22 | コリクサ コーポレイション | 単糖類及び二糖類に基づく化合物を用いた感染症及び他の疾患の予防的並びに治療的な処置 |
AU8100101A (en) | 2000-08-04 | 2002-02-18 | Corixa Corp | New immunoeffector compounds |
US6911434B2 (en) | 2002-02-04 | 2005-06-28 | Corixa Corporation | Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds |
US6525028B1 (en) | 2002-02-04 | 2003-02-25 | Corixa Corporation | Immunoeffector compounds |
US7030094B2 (en) | 2002-02-04 | 2006-04-18 | Corixa Corporation | Immunostimulant compositions comprising an aminoalkyl glucosaminide phosphate and QS-21 |
US7288640B2 (en) * | 2002-07-08 | 2007-10-30 | Corixa Corporation | Processes for the production of aminoalkyl glucosaminide phosphate and disaccharide immunoeffectors, and intermediates therefor |
IL166178A0 (en) | 2002-07-08 | 2006-01-15 | Corixa Corp | Processes for the production of aminoalkyl glucosaminide phosphate and disaccharide immunoeffectors and intermediates therefor |
RU2389732C2 (ru) | 2003-01-06 | 2010-05-20 | Корикса Корпорейшн | Некоторые аминоалкилглюкозаминидфосфатные производные и их применение |
US8312249B1 (en) | 2008-10-10 | 2012-11-13 | Apple Inc. | Dynamic trampoline and structured code generation in a signed code environment |
FR2957821B1 (fr) | 2010-03-24 | 2014-08-29 | Inst Francais Du Petrole | Nouvelle zone de regeneration du catalyseur divisee en secteurs pour unites catalytiques regeneratives |
-
2004
- 2004-07-08 US US10/888,683 patent/US7960522B2/en active Active
-
2005
- 2005-06-24 RU RU2007104781/04A patent/RU2007104781A/ru unknown
- 2005-06-24 SI SI200531983T patent/SI1776375T1/sl unknown
- 2005-06-24 ZA ZA200700996A patent/ZA200700996B/xx unknown
- 2005-06-24 EP EP15161738.8A patent/EP2940027A1/en not_active Withdrawn
- 2005-06-24 JP JP2007520338A patent/JP2008505897A/ja active Pending
- 2005-06-24 WO PCT/US2005/022522 patent/WO2006016997A2/en active Application Filing
- 2005-06-24 PT PT57855504T patent/PT1776375E/pt unknown
- 2005-06-24 TR TR2007/01350T patent/TR200701350T1/xx unknown
- 2005-06-24 CA CA002573059A patent/CA2573059A1/en not_active Abandoned
- 2005-06-24 MX MX2007000331A patent/MX2007000331A/es unknown
- 2005-06-24 BR BRPI0513144-8A patent/BRPI0513144A/pt not_active Application Discontinuation
- 2005-06-24 DK DK05785550.4T patent/DK1776375T3/en active
- 2005-06-24 CN CNA2005800294095A patent/CN101010328A/zh active Pending
- 2005-06-24 PL PL05785550T patent/PL1776375T3/pl unknown
- 2005-06-24 NZ NZ552790A patent/NZ552790A/en not_active IP Right Cessation
- 2005-06-24 HU HUE05785550A patent/HUE025324T2/en unknown
- 2005-06-24 AU AU2005272076A patent/AU2005272076B2/en not_active Ceased
- 2005-06-24 ES ES05785550.4T patent/ES2541306T3/es active Active
- 2005-06-24 EP EP05785550.4A patent/EP1776375B1/en active Active
-
2007
- 2007-01-08 IL IL180599A patent/IL180599A/en active IP Right Grant
- 2007-01-31 MA MA29644A patent/MA28758B1/fr unknown
- 2007-02-07 NO NO20070699A patent/NO340869B1/no unknown
- 2007-04-30 HK HK07104639.2A patent/HK1099308A1/zh not_active IP Right Cessation
-
2008
- 2008-06-05 ZA ZA200804906A patent/ZA200804906B/en unknown
-
2011
- 2011-05-24 US US13/115,011 patent/US20120058148A1/en not_active Abandoned
-
2015
- 2015-07-01 CY CY20151100568T patent/CY1116571T1/el unknown
-
2016
- 2016-05-04 HK HK16105082.0A patent/HK1217105A1/zh unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1217105A1 (zh) | 些氨基烷基氨基葡糖苷磷酸酯化合物及其用途 | |
IL169540A0 (en) | Certain aminoalkyl glucosaminide phosphate compounds and their use | |
EP1669046A4 (en) | ABSORBENT ARTICLE | |
PL1827335T3 (pl) | Wyrób chłonny | |
EP1818031A4 (en) | ABSORBENT ARTICLE | |
PL1827336T5 (pl) | Wyrób chłonny | |
EP1779826A4 (en) | VOIDABLE ARTICLE | |
PL1547555T3 (pl) | Wyrób chłonny | |
TWI317632B (en) | Absorbent article | |
TWI347181B (en) | Absorbent article | |
GB0427723D0 (en) | Compounds and their use | |
AU156464S (en) | Incontinence pant | |
GB0425538D0 (en) | Compounds and their uses | |
GB0421767D0 (en) | Compounds and their medical uses | |
GB0421766D0 (en) | Compounds and their medical uses | |
GB0409377D0 (en) | Compounds and their use | |
GB0423234D0 (en) | Compounds and their use | |
GB0409379D0 (en) | Compounds and their use | |
GB0410830D0 (en) | Compounds and their use | |
GB0410831D0 (en) | Compounds and their use | |
GB0410832D0 (en) | Compounds and their use | |
GB0410833D0 (en) | Compounds and their use | |
GB0401244D0 (en) | Compounds and their use | |
GB0411071D0 (en) | Compounds and their use | |
GB0401243D0 (en) | Compounds and their use |